BR112013009371A2 - composição tópica farmacêutica de mupirocina - Google Patents

composição tópica farmacêutica de mupirocina

Info

Publication number
BR112013009371A2
BR112013009371A2 BR112013009371A BR112013009371A BR112013009371A2 BR 112013009371 A2 BR112013009371 A2 BR 112013009371A2 BR 112013009371 A BR112013009371 A BR 112013009371A BR 112013009371 A BR112013009371 A BR 112013009371A BR 112013009371 A2 BR112013009371 A2 BR 112013009371A2
Authority
BR
Brazil
Prior art keywords
mupirocin
group
topical composition
pharmaceutical topical
pharmaceutical
Prior art date
Application number
BR112013009371A
Other languages
English (en)
Other versions
BR112013009371B1 (pt
Inventor
Beatriz Goñi Allo
Carlos González Ojer
Cayetana Yárnoz De Miguel
Fiona Pastor Fernández
Original Assignee
Ojer Pharma S L Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ojer Pharma S L Lab filed Critical Ojer Pharma S L Lab
Publication of BR112013009371A2 publication Critical patent/BR112013009371A2/pt
Publication of BR112013009371B1 publication Critical patent/BR112013009371B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição tópica farmacêutica de mupirocina. a presente invenção refere-se a uma composição tópica em gel anidra de mupirocina ou seus sais, compreendendo: a) uma base lipofílica selecionada a partir do grupo que consiste em petrolato, triglicerídeos de cadeia média, ministato de isopropila e misturas dos mesmos b) um biodesivo selecionado a partir do grupo que compreende polivinilpirrolidona e polimetacrilatos; e c) um slvente selecionado a patir do grupo que compreende entanol, propanol e isopropanol; que é estável e mostra um tempo de permanência aumentado do ingrediente ativo na pele, resultando em um efeito clínico melhorado no tratamento de infecções cutâneas bacterianas, enquanto mantém o perfil de segurança do produto farmacêutico comercial.
BR112013009371A 2010-10-20 2011-10-19 composição tópica farmacêutica de mupirocina BR112013009371B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382274A EP2444067A1 (en) 2010-10-20 2010-10-20 Anhydrous gel comprising mupirocin
PCT/EP2011/068242 WO2012052472A1 (en) 2010-10-20 2011-10-19 Pharmaceutical topical composition of mupirocin

Publications (2)

Publication Number Publication Date
BR112013009371A2 true BR112013009371A2 (pt) 2016-07-26
BR112013009371B1 BR112013009371B1 (pt) 2019-08-27

Family

ID=44050874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009371A BR112013009371B1 (pt) 2010-10-20 2011-10-19 composição tópica farmacêutica de mupirocina

Country Status (16)

Country Link
US (1) US9205149B2 (pt)
EP (2) EP2444067A1 (pt)
JP (1) JP5954745B2 (pt)
KR (1) KR101776362B1 (pt)
CN (1) CN103189048B (pt)
AU (1) AU2011317636B2 (pt)
BR (1) BR112013009371B1 (pt)
CA (1) CA2814103C (pt)
ES (1) ES2531846T3 (pt)
MX (1) MX2013004394A (pt)
NZ (1) NZ609655A (pt)
PL (1) PL2629756T3 (pt)
PT (1) PT2629756E (pt)
RU (1) RU2563840C2 (pt)
WO (1) WO2012052472A1 (pt)
ZA (1) ZA201302560B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006201A1 (en) * 2012-07-06 2014-01-09 Leo Pharma A/S A topical composition comprising a film-forming polymer for delivering an active ingredient to skin
EP2742932A1 (en) 2012-12-17 2014-06-18 Laboratorios Ojer Pharma S.L. Gel compositions
WO2016133471A1 (en) 2015-02-20 2016-08-25 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A. Ş. A topical composition comprising mupirocin and dexpanthenol
CA3033570C (en) * 2015-08-17 2022-12-06 Sidmak Laboratories (India) Pvt. Ltd. Topical film delivery system
KR101717699B1 (ko) 2016-02-11 2017-03-17 아이큐어 주식회사 카타플라스마제용 자외선 경화형 하이드로젤 수지, 하이드로젤 및 이를 포함하는 카타플라스마제
WO2020141482A1 (en) * 2019-01-04 2020-07-09 Glenmark Specialty S.A. Pharmaceutical compositions comprising mupirocin
CN110090198B (zh) * 2019-05-09 2020-02-21 哈尔滨乾佰纳生物药业有限公司 一种具有生物粘附性的缓释型口腔溃疡凝胶及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530796D0 (en) * 1985-12-13 1986-01-22 Beecham Group Plc Pharmaceutical composition
GB8615669D0 (en) * 1986-06-26 1986-07-30 Beecham Group Plc Treatment
IE59628B1 (en) 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
GB9321876D0 (en) * 1993-10-22 1993-12-15 Smithkline Beecham Corp Novel composition
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
EP1033969A1 (en) * 1997-09-11 2000-09-13 Smithkline Beecham Plc Compositions adapted for prolonged residence in the nasal pharynx
IL137363A (en) 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
AU2002950506A0 (en) * 2002-07-31 2002-09-12 Soltec Research Pty Ltd Percutaneous delivery system
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20050123576A1 (en) * 2003-12-03 2005-06-09 Ilana Lavon Mupirocin compositions for topical use, an improved process of making same and methods of using same
KR20070080823A (ko) * 2007-01-31 2007-08-13 주식회사 티디에스팜 활성약물 함유 상처 치료용 하이드로겔 제제

Also Published As

Publication number Publication date
CN103189048B (zh) 2014-11-26
MX2013004394A (es) 2013-08-21
CN103189048A (zh) 2013-07-03
WO2012052472A1 (en) 2012-04-26
RU2563840C2 (ru) 2015-09-20
EP2629756B1 (en) 2014-12-24
RU2013122845A (ru) 2014-11-27
CA2814103C (en) 2018-06-12
NZ609655A (en) 2014-08-29
CA2814103A1 (en) 2012-04-26
ES2531846T3 (es) 2015-03-20
US9205149B2 (en) 2015-12-08
BR112013009371B1 (pt) 2019-08-27
AU2011317636A1 (en) 2013-05-23
KR20130124504A (ko) 2013-11-14
ZA201302560B (en) 2014-06-25
US20130267587A1 (en) 2013-10-10
EP2444067A1 (en) 2012-04-25
PT2629756E (pt) 2015-05-21
EP2629756A1 (en) 2013-08-28
JP2013543518A (ja) 2013-12-05
PL2629756T3 (pl) 2015-06-30
JP5954745B2 (ja) 2016-07-20
AU2011317636B2 (en) 2016-05-12
KR101776362B1 (ko) 2017-09-07

Similar Documents

Publication Publication Date Title
BR112013009371A2 (pt) composição tópica farmacêutica de mupirocina
BR112018001811A2 (pt) composição de bactérias láticas para uso no tratamento de infecções devidas a pro-pionibacterium acnes e em particular para acne
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
BR112014013661A8 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
BR112014012056A8 (pt) compostos farmacêuticos
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
CL2012001597A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona o una sal de esta, y un portador farmaceuticamente aceptable; util para tratar fibrilacion auricular.
BR112015018418A2 (pt) métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
BR112015000011A2 (pt) compostos de triazol como medicamentos antivirais
BR112014018795A2 (pt) derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase
MX2013004099A (es) Conjunto de juguete de construccion.
BR112012029170A2 (pt) fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo como um princípio ativo
BR112014028813A2 (pt) 5-amino[1,4]tiazinas como inibidores bace1
BR112014006180A2 (pt) 4, 5, 6, 7-tetraidro-1h-pirazol [4, 3-c] piridinas substituídas, seu uso como medicamento e preparações farmacêuticas que compreendem as mesmas
BR112015029619A2 (pt) derivados de 1,3-diaminociclopentano carboxamida
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
TN2015000037A1 (en) Transdermal formulation containing cox inhibitors
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
BR112018000496A2 (pt) combinações farmacêuticas e seu uso
ATE441408T1 (de) Zusammensetzung enthältend retinoid und beta- aminoisobuttersäurederivate
BR112014005583A2 (pt) 4,5,6,7-tetra-hidro-1h-pirazolo[4,3-c]piridinas substituídas com indanila, seu uso como medicamento, e preparações farmacêuticas que as contêm

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/10/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/10/2011, OBSERVADAS AS CONDICOES LEGAIS